



Gliolab

GLIOBLASTOMA FOUNDATION

COMPREHENSIVE GENOMIC PROFILING OF GLIOBLASTOMA WITH PGDX ELIO™ TISSUE COMPLETE


A Guide for Patients and Providers



gliolab.org

TABLE OF CONTENTS

- 1** What is Comprehensive Genomic Profiling?
- 2** About PGDx Elio tissue complete
- 3** Why Genomic Profiling is Essential for Glioblastoma
- 4** What the Test Detects
- 5** How the Results Are Used
- 6** FDA Clearance and Clinical Standards
- 7** CPT Code and Reimbursement Information
- 8** Accessing the Test Through Gliolab
- 9** Frequently Asked Questions (FAQs)
- 10** Glossary of Key Genomic Terms



WHAT IS COMPREHENSIVE GENOMIC PROFILING (CGP)?

Comprehensive Genomic Profiling (CGP) uses next-generation DNA sequencing to detect a wide range of genetic alterations in cancer. Unlike limited single-gene tests, CGP provides a complete molecular snapshot of the tumor, which can reveal key targets for therapy or clinical trials.



About PGDx elio™ tissue complete

PGDx elio™ tissue complete is a DNA-based, FDA-cleared comprehensive genomic profiling assay that analyzes 505 cancer-associated genes using DNA extracted from FFPE tumor tissue.

Key features:

- Only uses DNA

Detects:

- Single nucleotide variants (SNVs)
- Small insertions and deletions (indels)
- Copy number alterations (CNAs)
- Selected genomic rearrangements detectable through DNA analysis

Calculates:

- Tumor Mutational Burden (TMB)
- Microsatellite Instability (MSI)

Designed for solid tumors, PGDx elio™ tissue complete is particularly valuable in complex, treatment-resistant cancers like glioblastoma.




WHY GENOMIC PROFILING IS ESSENTIAL FOR GLIOBLASTOMA

Glioblastoma is one of the most genomically diverse and aggressive brain tumors. No two tumors are exactly alike. Molecular profiling helps physicians:

- **Confirm diagnostic classification**
 - According to WHO 2021 (e.g., IDH-wildtype) guidelines
- **Detect oncogenic drivers**
 - Including EGFR amplification, CDKN2A deletion, PTEN mutation, and others
- ***Guide treatment decisions***
 - Identify targeted treatment options outside of the standard of care
- ***Match patients to clinical trials***
- ***Predict treatment resistance or sensitivity***

Glioblastoma cannot be fully understood—or treated optimally—without understanding its molecular makeup.

A photograph of two male scientists in a laboratory. The scientist in the foreground is wearing a white lab coat and a blue tie, looking through a microscope. The scientist in the background is also in a lab coat and glasses, working at a bench. The lab is filled with various glassware, including beakers and flasks, some containing colored liquids. A bright circular light fixture is visible above the work area.

What the Test Detects

PGDx elio™ tissue complete reports on:

- Mutations in 505+ genes, including:
 - TP53, PTEN, EGFR, NF1, TERT, CDKN2A, PIK3CA, RB1 and others
- Copy number gains and losses, e.g.:
 - EGFR amplification
 - CDK4 gain, CDKN2A/B loss
- Select structural alterations
 - detectable through DNA alone
- Tumor Mutational Burden (TMB) – A biomarker for potential immunotherapy response
- Microsatellite Instability (MSI) – Rare in glioblastoma but critical to assess
- IDH1 and IDH2 mutation status
 - essential to confirm that the tumor is indeed glioblastoma and not another glioma subtype.

***All Results are interpreted with regard to:
potential therapies, resistance patterns, and trial opportunities.***




HOW THE RESULTS ARE USED

The test yields a comprehensive, clinically annotated report, which can be used to:

- **Refine diagnosis** (e.g., confirm IDH-wildtype glioblastoma)
- **Identify targetable mutations**
- **Justify off-label or compassionate-use therapies**
- **Guide enrollment into precision oncology trials**
- **Predict prognosis and likely treatment resistance**

Examples Clinical Scenarios:

- **EGFR amplification or variant** → Suggests eligibility for EGFR-targeted clinical trials
- **High TMB** → May qualify for checkpoint inhibitor trials
- **CDKN2A loss** or **CDK4 amplification** → Could indicate responsiveness to CDK4/6 inhibitors
- **PTEN mutation** → May inform use of PI3K/mTOR-targeted agents in trial settings



FDA Clearance and Clinical Standards

PGDx elio™ tissue complete is:

- FDA-cleared (510(k)) for use in solid tumors
- Validated for DNA from FFPE tissue, making it compatible with archived surgical specimens
- Run in a CLIA-certified, CAP-accredited laboratory and meets *rigorous analytical performance standards in sensitivity, specificity, and accuracy*



PERSONALIZED TREATMENT ROADMAP

At Gliolab, we help you and your doctor discover the treatment paths designed uniquely for you — based on your tumor profile.

Our **Comprehensive Genomic Profiling** test does more than provide data; it's an important part of our personalized treatment roadmap tailored to each patient's tumor biology.

Rather than relying on one-size-fits-all protocols, care teams can use our detailed genomic insights to pinpoint therapies most likely to be effective, explore relevant clinical trials, and avoid treatments unlikely to be effective.

With Gliolab, patients and their physicians gain clarity, direction, and a powerful tool for navigating one of the most complex and aggressive brain cancers.

Personalized Glioblastoma Care Starts at Gliolab.

A background image of a laboratory. In the foreground, a woman with blonde hair and glasses is looking at a computer monitor displaying a DNA microarray or similar genomic data. To her left, a man is partially visible, also looking at a screen. In the background, another person is working at a bench. The lab is equipped with various glassware, including beakers and test tubes, and a microscope is visible on the right. The overall tone is professional and scientific.

Accessing the Test Through Gliolab

Gliolab, the CLIA-registered molecular testing laboratory of the Glioblastoma Foundation, provides this test to glioblastoma patients and physicians nationwide.

To order:

- Tumor tissue (FFPE block or unstained slides) must be submitted by a neurosurgeon, pathologist, or treating oncologist
- Turnaround time: ~7–10 business days after receipt of sample
- Comprehensive report delivered to ordering provider
- Expert support: Gliolab's molecular tumor board is available for case review.

Ordering and Contact:

 www.gliolab.org

 genomictesting@gliolab.org

 1-855-GLIOLAB



FREQUENTLY ASKED QUESTIONS (FAQS)

Q: Does this test use both DNA and RNA?

A: No. PGDx elio™ tissue complete is a DNA-based test. It does not analyze RNA or detect gene fusions that require RNA input. This test is one part of your complete personalized treatment roadmap. Whole-genome DNA methylation testing and gene fusion mutation detection complete your personalized treatment roadmap.

Q: Can the test be performed on stored tumor tissue?


A: Yes. It uses FFPE tissue and is compatible with most stored surgical tumor samples.

Q: Is this test still useful if I already had limited molecular testing?

A: Yes. PGDx elio covers *over 500 cancer-related genes*—far more than most hospital panels—and provides broader insights into glioblastoma tumor biology.

Q: How long does it take to get results?

A: Typically 7–10 business days from sample receipt.



Glossary of Key Genomic Terms

- **FFPE:** Formalin-Fixed Paraffin-Embedded; a method of preserving tissue for testing.
- **IDH-Wildtype:** Tumors without mutations in IDH genes; necessary to classify a tumor as glioblastoma.
- **EGFR Amplification:** Extra copies of the EGFR gene; common in glioblastoma.
- **TMB:** Tumor Mutational Burden; number of mutations per megabase of DNA.
- **MSI:** Microsatellite Instability; reflects DNA mismatch repair defects.
- **Copy Number Alteration:** A gain or loss of copies of a gene, influencing tumor behavior.



Contact and Support

*For help with new or existing test orders, please contact our support team at the phone or email below, and we'll provide assistance. Our hours of operation are Monday through Friday 8AM to 6PM Eastern Time. For providers who would like to order a test in the United States (US) please visit our website at **www.gliolab.org** for ordering instructions and more.*

Phone: (919) 309-1489

Email: support@gliolab.org

